A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia, the most common and lethal form of adult leukemia.
A drug used to treat kidney cancer also targets a genetic mutation active in about one third of patients with acute myeloid leukemia, the most common and lethal form of adult leukemia.